Hopp til innhold
NHI.no
Annonse

Aspergillose: Behandling

Innhold i artikkelen

Aspergillose behandles med soppdrepende midler som gis i tablettform eller direkte i blodet. Avgjørende for prognosen er at man oppdager tilstanden tidlig og før pasienten er svært svekket. Med tidlig behandling kan tilstanden helbredes i de fleste tilfellene. 

Dette dokumentet er basert på det profesjonelle dokumentet Aspergillose . Referanselisten for dette dokumentet vises nedenfor

  1. Folkehelseinstituttet. Aspergillose - veileder for helsepersonell. Smittervernveilederen, sist oppdatert 01.12.2018. Siden lest 06.02.2025 fhi.no
  2. Ramesh M, Chandrasekar P. Aspergillosis. BestPractice, last updated Aug 15, 2013.
  3. Nordøy I, Gaustad P. Resistensproblemer bed behandling av invasive soppinfeksjoner. Tidsskr Nor Legeforen 2008; 128: 2607-11. Tidsskrift for Den norske legeforening
  4. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250-260. PubMed
  5. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 89-96. PubMed
  6. Cruciani M, Mengoli C, Barnes R, Donnelly JP, Loeffler J, Jones BL, Klingspor L, Maertens J, Morton CO, White LP. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database of Systematic Reviews 2019, Issue 9. Art. No.: CD009551. DOI: 10.1002/14651858.CD009551.pub4. Accessed 10 February 2021. The Cochrane Library
  7. Koo S, Thomas HR, Daniels SD, et al. A breath fungal secondary metabolite signature to diagnose invasive aspergillosis. Clin Infect Dis 2014. doi:10.1093/cid/ciu725
  8. White SK, Schmidt RL, Walker BS, Hanson KE. (1→3)‐β‐D‐glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people. Cochrane Database of Systematic Reviews 2020, Issue 7. Art. No.: CD009833. DOI: 10.1002/14651858.CD009833.pub2. Accessed 10 February 2021. The Cochrane Library
  9. Jenks JD, Hoenig M. Treatment of Aspergillosis. J Fungi (Basel) 2018; 4: 98. pmid:30126229 PubMed
  10. Dladla M, Gyzenhout M, Marias G, Ghosh S. Azole resistance in Aspergillus fumigatus- comprehensive review. Arch Microbiol. 2024 Jun 15;206(7):305. PMID: 38878211. PubMed
  11. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-360. PubMed
  12. Maertens JS, Rahav G, Lee D-G, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021. pmid:33549194 PubMed
  13. Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 2015; 162: 81-9. doi:10.7326/M13-2508 DOI
  14. Center for Disease Control and Prevention. Disease listing: Aspergillosis. cdc.gov, 2009.
Annonse
Annonse